Jeffrey Weinberg, MD
Dermatology · Kew Gardens, NYNPI 1689660565
Payments from drug & device makers
Across 4,010 payments — averaging $1221.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$803K
- AbbVie$582K
- Novartis$553K
- Lilly USA, LLC$328K
- Eli Lilly$295K
- Regeneron$252K
- plus $2.1M from 49 others
Across 67 payments — averaging $1839.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$47K
- Ichnos Glenmark Innovation Inc$40K
- Glenmark Pharmaceuticals Inc., USA$32K
- Almirall LLC$5K
What the payments were for
- Consulting fees$227,99810%
- Speaking & faculty fees$1,812,48280%
- Travel & lodging$150,1307%
- Food & beverage$71,8743%
- Education$9350%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,898,708 in reported general payments places this provider in the 95th percentile of 1,151 dermatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 205 | $728,935 |
| Skyrizi PenRisankizumab-Rzaa | 29 | $556,998 |
| TremfyaGuselkumab | 42 | $551,797 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 68 | $485,992 |
| Taltz AutoinjectorIxekizumab | 68 | $451,372 |
| Dupixent SyringeDupilumab | 117 | $435,940 |
| OpzeluraRuxolitinib Phosphate | 180 | $356,447 |
| IlumyaTildrakizumab-Asmn | 13 | $221,950 |
| Cosentyx Unoready PenSecukinumab | 23 | $188,567 |
| Bimzelx AutoinjectorBimekizumab-Bkzx | 14 | $187,986 |
| OtezlaApremilast | 30 | $142,971 |
| Taltz SyringeIxekizumab | 15 | $121,283 |
| Tacrolimus | 379 | $96,507 |
| Humira(Cf)Adalimumab | 12 | $81,738 |
| Clobetasol Propionate | 548 | $37,722 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonTremfya | $188,767 | $551,79742 claims |
| Incyte CorporationOpzelura | $803,355 | $356,447180 claims |
| Sun Pharmaceutical Industries Inc.Ilumya | $229,946 | $221,95013 claims |
| AmgenOtezla | $180,143 | $142,97130 claims |
| AbbVieHumira(Cf) | $581,644 | $81,73812 claims |
| Arcutis Biotherapeutics, Inc.Zoryve | $68,803 | $36,11544 claims |
| Dermavant Sciences, Inc.Vtama | $80,711 | $21,39016 claims |
| PfizerEucrisa | $215,662 | $17,19823 claims |
| Dermira, Inc.Qbrexza | $12,378 | $10,16316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,151 dermatology providers in New York.
Other dermatology in Kew Gardens
- Emma GuttmanNew York$35.3M
- Saakshi KhattriNew York$15.4M
- James KruegerNew York$6.3M
- Michael CameronNew York$5.8M
- Mark LebwohlNew York$5.8M
- Andrew AlexisNew York$5.7M
- John TuRochester$5.4M
- Neil SadickNew York$4.2M
- Alice GottliebSomers$3.8M
- Orit MarkowitzNew York$3.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.